Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Doxorubicin 13Specimen Handling 12pembrolizumab 11Magnetic Resonance Spectroscopy 10Biopsy 10Cyclophosphamide 9X-Rays 7Ifosfamide 7Radiotherapy 6Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Nivolumab 5tazemetostat 4palbociclib 4fludarabine 4atezolizumab 4Temozolomide 4Radiation 4Nuclear Medicine Department, Hospital 4Irinotecan 4larotrectinib 3cabozantinib 3Surveys and Questionnaires 3Ipilimumab 3Carboplatin 3Bevacizumab 3ulixertinib 2tipifarnib 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × aflibercept × 90 days × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡